Fibrates: Therapeutic potential for diabetic nephropathy?
Abstract Despite intensive glucose-lowering treatment and advanced therapies for cardiovascular risk factors, such as hypertension and dyslipidaemia, diabetes mellitus with its macro- and microvascular complications remains a major health problem. Especially diabetic nephropathy is a leading cause o...
Gespeichert in:
| Veröffentlicht in: | European journal of internal medicine 2012-06, Vol.23 (4), p.309-316 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 316 |
|---|---|
| container_issue | 4 |
| container_start_page | 309 |
| container_title | European journal of internal medicine |
| container_volume | 23 |
| creator | Kouroumichakis, I Papanas, N Zarogoulidis, P Liakopoulos, V Maltezos, E Mikhailidis, D.P |
| description | Abstract Despite intensive glucose-lowering treatment and advanced therapies for cardiovascular risk factors, such as hypertension and dyslipidaemia, diabetes mellitus with its macro- and microvascular complications remains a major health problem. Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing. Peroxisome proliferator-activated receptor-α (PPAR-α), a member of a large nuclear receptor superfamily, is expressed in several tissues including the kidney. Recently, experimental data have suggested that PPAR-α activation plays a pivotal role in the regulation of fatty acid oxidation, lipid metabolism, inflammatory and vascular responses, and might regulate various metabolic and intracellular signalling pathways that lead to diabetic microvascular complications. This review examines the role of PPAR-α activation in diabetic nephropathy and summarises data from experimental and clinical studies on the emerging therapeutic potential of fibrates in diabetic nephropathy. |
| doi_str_mv | 10.1016/j.ejim.2011.12.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1011536969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0953620511003141</els_id><sourcerecordid>1011536969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-f3cadf920496537571e92bc159823da91a72baa3d88e8d7b87cc9feea57fbf913</originalsourceid><addsrcrecordid>eNp9kUtLxDAUhYMoOj7-gAuZpZvW3GTaNCKKDL5gwIW6Dml6y6T2ZdIK8-9NGXXhwlXg8p0D-Q4hp0BjoJBeVDFWtokZBYiBxZSKHTKDTMiIZizbJTMqEx6ljCYH5ND7ilIQlPJ9csBYklIu0hmR9zZ3ekB_OX9do9M9joM1874bsB2srudl5-aF1TlO5xb7tet6Paw3N8dkr9S1x5Pv94i83d-9Lh-j1fPD0_J2FZmFEENUcqOLUjK6kGnCRSIAJcsNJDJjvNAStGC51rzIMswKkWfCGFki6kSUeSmBH5HzbW_vuo8R_aAa6w3WtW6xG70KKiDhqUxlQNkWNa7z3mGpemcb7TYBmrhUVWpSpiZlCpgKykLo7Lt_zBssfiM_jgJwtQUw_PLTolPeWGwNFtahGVTR2f_7r__ETW1ba3T9jhv0VTe6NvhToHwIqJdptGkzgLAVLIB_AU9ZkY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1011536969</pqid></control><display><type>article</type><title>Fibrates: Therapeutic potential for diabetic nephropathy?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kouroumichakis, I ; Papanas, N ; Zarogoulidis, P ; Liakopoulos, V ; Maltezos, E ; Mikhailidis, D.P</creator><creatorcontrib>Kouroumichakis, I ; Papanas, N ; Zarogoulidis, P ; Liakopoulos, V ; Maltezos, E ; Mikhailidis, D.P</creatorcontrib><description>Abstract Despite intensive glucose-lowering treatment and advanced therapies for cardiovascular risk factors, such as hypertension and dyslipidaemia, diabetes mellitus with its macro- and microvascular complications remains a major health problem. Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing. Peroxisome proliferator-activated receptor-α (PPAR-α), a member of a large nuclear receptor superfamily, is expressed in several tissues including the kidney. Recently, experimental data have suggested that PPAR-α activation plays a pivotal role in the regulation of fatty acid oxidation, lipid metabolism, inflammatory and vascular responses, and might regulate various metabolic and intracellular signalling pathways that lead to diabetic microvascular complications. This review examines the role of PPAR-α activation in diabetic nephropathy and summarises data from experimental and clinical studies on the emerging therapeutic potential of fibrates in diabetic nephropathy.</description><identifier>ISSN: 0953-6205</identifier><identifier>EISSN: 1879-0828</identifier><identifier>DOI: 10.1016/j.ejim.2011.12.007</identifier><identifier>PMID: 22560376</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Creatinine - blood ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - drug therapy ; Diabetic Nephropathies - physiopathology ; Diabetic nephropathy ; Disease Progression ; Dyslipidaemia ; Fenofibrate - administration & dosage ; Fenofibrate - therapeutic use ; Fibrates ; Fibric Acids - pharmacology ; Fibric Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Hypolipidemic Agents - administration & dosage ; Hypolipidemic Agents - therapeutic use ; Internal Medicine ; Metabolic syndrome ; Peroxisome proliferator-activated receptor-α ; PPAR alpha - agonists ; PPAR alpha - physiology ; Thiazolidinediones - administration & dosage ; Thiazolidinediones - therapeutic use</subject><ispartof>European journal of internal medicine, 2012-06, Vol.23 (4), p.309-316</ispartof><rights>European Federation of Internal Medicine.</rights><rights>2011 European Federation of Internal Medicine.</rights><rights>Copyright © 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-f3cadf920496537571e92bc159823da91a72baa3d88e8d7b87cc9feea57fbf913</citedby><cites>FETCH-LOGICAL-c477t-f3cadf920496537571e92bc159823da91a72baa3d88e8d7b87cc9feea57fbf913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0953620511003141$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22560376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kouroumichakis, I</creatorcontrib><creatorcontrib>Papanas, N</creatorcontrib><creatorcontrib>Zarogoulidis, P</creatorcontrib><creatorcontrib>Liakopoulos, V</creatorcontrib><creatorcontrib>Maltezos, E</creatorcontrib><creatorcontrib>Mikhailidis, D.P</creatorcontrib><title>Fibrates: Therapeutic potential for diabetic nephropathy?</title><title>European journal of internal medicine</title><addtitle>Eur J Intern Med</addtitle><description>Abstract Despite intensive glucose-lowering treatment and advanced therapies for cardiovascular risk factors, such as hypertension and dyslipidaemia, diabetes mellitus with its macro- and microvascular complications remains a major health problem. Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing. Peroxisome proliferator-activated receptor-α (PPAR-α), a member of a large nuclear receptor superfamily, is expressed in several tissues including the kidney. Recently, experimental data have suggested that PPAR-α activation plays a pivotal role in the regulation of fatty acid oxidation, lipid metabolism, inflammatory and vascular responses, and might regulate various metabolic and intracellular signalling pathways that lead to diabetic microvascular complications. This review examines the role of PPAR-α activation in diabetic nephropathy and summarises data from experimental and clinical studies on the emerging therapeutic potential of fibrates in diabetic nephropathy.</description><subject>Animals</subject><subject>Creatinine - blood</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Diabetic Nephropathies - physiopathology</subject><subject>Diabetic nephropathy</subject><subject>Disease Progression</subject><subject>Dyslipidaemia</subject><subject>Fenofibrate - administration & dosage</subject><subject>Fenofibrate - therapeutic use</subject><subject>Fibrates</subject><subject>Fibric Acids - pharmacology</subject><subject>Fibric Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Hypolipidemic Agents - administration & dosage</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Internal Medicine</subject><subject>Metabolic syndrome</subject><subject>Peroxisome proliferator-activated receptor-α</subject><subject>PPAR alpha - agonists</subject><subject>PPAR alpha - physiology</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Thiazolidinediones - therapeutic use</subject><issn>0953-6205</issn><issn>1879-0828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtLxDAUhYMoOj7-gAuZpZvW3GTaNCKKDL5gwIW6Dml6y6T2ZdIK8-9NGXXhwlXg8p0D-Q4hp0BjoJBeVDFWtokZBYiBxZSKHTKDTMiIZizbJTMqEx6ljCYH5ND7ilIQlPJ9csBYklIu0hmR9zZ3ekB_OX9do9M9joM1874bsB2srudl5-aF1TlO5xb7tet6Paw3N8dkr9S1x5Pv94i83d-9Lh-j1fPD0_J2FZmFEENUcqOLUjK6kGnCRSIAJcsNJDJjvNAStGC51rzIMswKkWfCGFki6kSUeSmBH5HzbW_vuo8R_aAa6w3WtW6xG70KKiDhqUxlQNkWNa7z3mGpemcb7TYBmrhUVWpSpiZlCpgKykLo7Lt_zBssfiM_jgJwtQUw_PLTolPeWGwNFtahGVTR2f_7r__ETW1ba3T9jhv0VTe6NvhToHwIqJdptGkzgLAVLIB_AU9ZkY4</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Kouroumichakis, I</creator><creator>Papanas, N</creator><creator>Zarogoulidis, P</creator><creator>Liakopoulos, V</creator><creator>Maltezos, E</creator><creator>Mikhailidis, D.P</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Fibrates: Therapeutic potential for diabetic nephropathy?</title><author>Kouroumichakis, I ; Papanas, N ; Zarogoulidis, P ; Liakopoulos, V ; Maltezos, E ; Mikhailidis, D.P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-f3cadf920496537571e92bc159823da91a72baa3d88e8d7b87cc9feea57fbf913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Creatinine - blood</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Diabetic Nephropathies - physiopathology</topic><topic>Diabetic nephropathy</topic><topic>Disease Progression</topic><topic>Dyslipidaemia</topic><topic>Fenofibrate - administration & dosage</topic><topic>Fenofibrate - therapeutic use</topic><topic>Fibrates</topic><topic>Fibric Acids - pharmacology</topic><topic>Fibric Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Hypolipidemic Agents - administration & dosage</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Internal Medicine</topic><topic>Metabolic syndrome</topic><topic>Peroxisome proliferator-activated receptor-α</topic><topic>PPAR alpha - agonists</topic><topic>PPAR alpha - physiology</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Thiazolidinediones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kouroumichakis, I</creatorcontrib><creatorcontrib>Papanas, N</creatorcontrib><creatorcontrib>Zarogoulidis, P</creatorcontrib><creatorcontrib>Liakopoulos, V</creatorcontrib><creatorcontrib>Maltezos, E</creatorcontrib><creatorcontrib>Mikhailidis, D.P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kouroumichakis, I</au><au>Papanas, N</au><au>Zarogoulidis, P</au><au>Liakopoulos, V</au><au>Maltezos, E</au><au>Mikhailidis, D.P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibrates: Therapeutic potential for diabetic nephropathy?</atitle><jtitle>European journal of internal medicine</jtitle><addtitle>Eur J Intern Med</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>23</volume><issue>4</issue><spage>309</spage><epage>316</epage><pages>309-316</pages><issn>0953-6205</issn><eissn>1879-0828</eissn><abstract>Abstract Despite intensive glucose-lowering treatment and advanced therapies for cardiovascular risk factors, such as hypertension and dyslipidaemia, diabetes mellitus with its macro- and microvascular complications remains a major health problem. Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing. Peroxisome proliferator-activated receptor-α (PPAR-α), a member of a large nuclear receptor superfamily, is expressed in several tissues including the kidney. Recently, experimental data have suggested that PPAR-α activation plays a pivotal role in the regulation of fatty acid oxidation, lipid metabolism, inflammatory and vascular responses, and might regulate various metabolic and intracellular signalling pathways that lead to diabetic microvascular complications. This review examines the role of PPAR-α activation in diabetic nephropathy and summarises data from experimental and clinical studies on the emerging therapeutic potential of fibrates in diabetic nephropathy.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>22560376</pmid><doi>10.1016/j.ejim.2011.12.007</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0953-6205 |
| ispartof | European journal of internal medicine, 2012-06, Vol.23 (4), p.309-316 |
| issn | 0953-6205 1879-0828 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1011536969 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Creatinine - blood Diabetic Nephropathies - blood Diabetic Nephropathies - drug therapy Diabetic Nephropathies - physiopathology Diabetic nephropathy Disease Progression Dyslipidaemia Fenofibrate - administration & dosage Fenofibrate - therapeutic use Fibrates Fibric Acids - pharmacology Fibric Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Hypolipidemic Agents - administration & dosage Hypolipidemic Agents - therapeutic use Internal Medicine Metabolic syndrome Peroxisome proliferator-activated receptor-α PPAR alpha - agonists PPAR alpha - physiology Thiazolidinediones - administration & dosage Thiazolidinediones - therapeutic use |
| title | Fibrates: Therapeutic potential for diabetic nephropathy? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T12%3A13%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibrates:%20Therapeutic%20potential%20for%20diabetic%20nephropathy?&rft.jtitle=European%20journal%20of%20internal%20medicine&rft.au=Kouroumichakis,%20I&rft.date=2012-06-01&rft.volume=23&rft.issue=4&rft.spage=309&rft.epage=316&rft.pages=309-316&rft.issn=0953-6205&rft.eissn=1879-0828&rft_id=info:doi/10.1016/j.ejim.2011.12.007&rft_dat=%3Cproquest_cross%3E1011536969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1011536969&rft_id=info:pmid/22560376&rft_els_id=1_s2_0_S0953620511003141&rfr_iscdi=true |